A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in Taiwan

Who May Qualify: - Participants with all ages and diagnosis of moderate-severe hemophilia A without current and/or at least three years of un-detectable inhibitor (\<0.6 BU) - Participants with moderate to severe hemophilia A as defined by FVIII level ≤ 5% - Participants starting efanesoctocog alfa prophylaxis treatment as per standard of care no more than three months prior to the enrollment date - Participants aged 6 years and older are able to undergo MRI examinations (sedation given, if necessary, and per investigator discretion) - Participants are able to undergo joint examinations - Physician's decision to treat the participant with efanesoctocog alfa is made prior to and independently of participation in the study - Signed and dated willing to sign a consent form provided by the participant, or by the participant's legally acceptable representative for participants under the legal age before any study-related activities are undertaken. Assent should be obtained for pediatric participants according to local regulations Who Should NOT Join This Trial: - Participants with coagulation disorders other than hemophilia A - Participants diagnosed with other known bleeding disorder - Participants currently receive factor therapy and have signs of decreased response to FVIII therapy - Participants with a baseline Radiological Pettersson score (PS) of greater than 6 for each individual ankle - Enrollment in another concurrent clinical interventional study, or intake of an Investigational Medicinal Product within 3 months prior to inclusion in this study - Pregnant female participants The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial. Always talk to your doctor about whether this trial is right for you.